SPRED1 and acute myeloid leukemia: We next analyzed the correlations of SPRED1 mRNA expression in BMs of 113 AML patients with a series of prognostic relevant clinical and laboratory parameters of AML including, white blood cell (WBC) count, hemoglobin (Hb) concentration, platelet (PLT) count and higher percent of blast cells in bone marrow (>72% comparing to the average blast ratio in bone marrow), FAB subtypes, and chromosomal abnormalities.